Lonza Forms Agreement to Manufacture Acumen Pharmaceuticals’ AD mAb Therapy

Under a collaboration agreement, Lonza will manufacture sabirnetug, Acumen Pharmaceuticals’ mAb in clinical development for treating Alzheimer’s disease.